CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Incontinence - urinary, in women - Management
What are the contraindications and cautions for duloxetine?
- Duloxetine is contraindicated in people:
- Taking monoamine oxidase inhibitors.
- Taking a CYP1A2 inhibitor (such as fluvoxamine or ciprofloxacin) — combination results in elevated plasma concentration of duloxetine.
- With hepatic impairment.
- With severe renal impairment (creatinine clearance less than 30 mL/min; approximately stage 4 CKD [chronic kidney disease]).
- With uncontrolled hypertension — there is a potential risk of hypertensive crisis.
- Prescribe duloxetine with caution in people with:
- Increased intra-ocular pressure, or those at risk of acute narrow-angle glaucoma — mydriasis has been reported in association with duloxetine.
- Epilepsy — concomitant treatment may precipitate seizures.
- A history of mania or a diagnosis of bipolar disorder — concomitant treatment may precipitate a mixed or manic episode. If this occurs, stop treatment with duloxetine.
[ABPI Medicines Compendium, 2008a]
© NHS Institute for Innovation and Improvement